Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 14;41(10):2571–2582. doi: 10.1177/0271678X211007949

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

PMC Copyright notice

Figure 3. — Magnetic resonance imaging (MRI) (a) and positron emission tomography (PET) (b) images of the monkey with Designer Receptors Exclusively Activated by Designer Drug (DREADD) injected into the right amygdala. The T1-weighted MRI (a) shows the contrast enhancer (Mn⁺⁺) at the injection site (marked with arrow). PET images (b) display the calculated values of binding corrected for the free fraction in plasma of the radioligand (V_T/f_P). The baseline image of [¹¹C]deschloroclozapine ([¹¹C]DCZ) compared to that of [¹¹C]clozapine ([¹¹C]CLZ) clearly shows greater contrast between the injection site (marked with an arrow) and the surrounding brain. Blockade by clozapine-N-oxide (CNO) (10 mg/kg i.v.) and the nonradioactive ligand (self-block 0.1 mg/kg i.v.) were 70–83% complete, based on Lassen analysis.